Cited by 520Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerCancer Mechanisms and Therapy

The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, Kanaga, Lane, David P.·2018·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2017.151

Open this paper in CoChat — free account

Abstract

TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated gene across all cancer types. The presence of mutant p53 predisposes to cancer development, promotes the survival of cancer cells, and is associated with ineffective therapeutic responses and unfavourable prognoses. Despite these effects, no drug that abrogates the oncogenic functions of mutant p53 has yet been approved for the treatment of cancer. Current investigational therapeutic strategies are mostly aimed at restoring the wild-type activity of mutant p53, based on the assumption that all p53 mutants are functionally equal. Our increasing knowledge of mutant forms of p53, however, supports the antithetical hypothesis that not all p53 mutants have equivalent cellular effects; hence, a judicious approach to therapeutic targeting of mutant p53 is required. In this Review, we propose a categorization of the major classes of p53 mutants based on their functionality in tumour suppression and response to therapy. The emerging picture is that the mutations across TP53 form a 'rainbow of mutants', with varying degrees of functionality and different pathobiological consequences, necessitating the use of diverse therapeutic strategies to selectively target specific classes of mutation. The utility of this knowledge of TP53 mutations in developing selective therapeutic options, and in facilitating clinical decision-making is discussed.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2017.151

Cites

182 of 182 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Self-citation
p53 in health and disease
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,351
Self-citation

Show all 178 references

Sorted by citations

Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C. Y., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 895
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 771
Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636
Somatic mutations precede acute myeloid leukemia years before diagnosis
Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M. S., Cheang, G., Lee, S., Samuel, M., Ritchie, E. K., Guzman, M. L., Ballman, K. V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0081-z · Cited by 619
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 576
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M. Y., Martinelli, G., Daver, N. G., Papayannidis, C., Wei, A. H., Higgins, B., Ott, M., Mascarenhas, J. O., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 380
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
Kadosh, E., Snir-Alkalay, I., Venkatachalam, A., May, S., Lasry, A., Elyada, E., Zinger, A., Shaham, M., Vaalani, G., Mernberger, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2541-0 · Cited by 378
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 355
Deubiquitinase-targeting chimeras for targeted protein stabilization
Henning, N. J., Boike, L., Spradlin, J. N., Ward, C. C., Liu, G., Zhang, E., Belcher, B. P., Brittain, S. M., Hesse, M. J., Dovala, D., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00971-2 · Cited by 344
The approved gene therapy drugs worldwide: from 1998 to 2019
Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 310
The Role of p53 Signaling in Colorectal Cancer
Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 350
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 334
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 267
Mutant p53 in cancer therapy—the barrier or the path
Zhou, X. Y., Hao, Q., & Lu, H. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy072 · Cited by 249
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223
Control of metabolism by p53 – Cancer and beyond
Labuschagne, C. F., Zani, F., & Vousden, K. H. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.001 · Cited by 227
Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer
Liu, H., Liu, Y., Yang, F., Zhang, L., Zhang, F., Hu, X., Shao, Z., & Li, D. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa130 · Cited by 210
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
Sun, H., Liu, S. M., Zhou, J., Xu, J., Zhang, H.-K., Yan, H., Huan, J., Dai, P., Xu, C., Su, J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102990 · Cited by 205
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 208
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Cao, X., Hou, J., An, Q., Assaraf, Y. G., & Wang, X. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100671 · Cited by 177
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
The many faces of p53: something for everyone
Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163
TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 184
Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Lo, W. M., Parkhurst, M. R., Robbins, P. F., Tran, E., Lu, Y., Jia, L., Gartner, J. J., Pasetto, A., Deniger, D. C., Malekzadeh, P., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0686 · Cited by 162
Current developments of targeting the p53 signaling pathway for cancer treatment
Huang, J. L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107720 · Cited by 157
p53 and metabolism: from mechanism to therapeutics
Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 159
Polyamines: their significance for maintaining health and contributing to diseases
Xuan, M., Gu, X., Li, J., Huang, D., Chen, X., & He, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01373-0 · Cited by 169
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Stiewe, T., & Haran, T. E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.05.001 · Cited by 143
Understanding p53 functions through p53 antibodies
Sabapathy, K., & Lane, D. P. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz010 · Cited by 139
Self-citation
Metabolic Modulation of the Tumor Microenvironment Leads to Multiple Checkpoint Inhibition and Immune Cell Infiltration
Kolb, D., Kolishetti, N., Surnar, B., Sarkar, S., Guin, S., Shah, A. S., & Dhar, S. (2020) · ACS Nano · doi:10.1021/acsnano.9b10037 · Cited by 137
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001101 · Cited by 133
p53 as a hub in cellular redox regulation and therapeutic target in cancer
Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123
Emerging Roles of p53 Family Members in Glucose Metabolism
Itahana, Y., & Itahana, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030776 · Cited by 123
Spaceflight and simulated microgravity suppresses macrophage development via altered RAS/ERK/NFκB and metabolic pathways
Shi, L., Tian, H., Wang, P., Li, L., Zhang, Z., Zhang, J., & Zhao, Y. X. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0346-6 · Cited by 115
Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
Best, S. A., Ding, S., Kersbergen, A., Dong, X., Song, J.-Y., Xie, Y., Reljic, B., Li, K., Vince, J. E., Rathi, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12164-y · Cited by 108
Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer
Boullosa, L. F., Loenhout, J. V., Flieswasser, T., Waele, J. D., Hermans, C., Lambrechts, H. A. J., Cuypers, B., Laukens, K., Bartholomeus, E., Siozopoulou, V., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101949 · Cited by 111
Acute Myeloid Leukemia: The Good, the Bad, and the Ugly
Kuykendall, A. T., Duployez, N., Boissel, N., Lancet, J. E., & Welch, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199519 · Cited by 115
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients
Hassin, O., Nataraj, N. B., Shreberk‐Shaked, M., Aylon, Y., Yaeger, R. D., Fontemaggi, G., Mukherjee, S., Maddalena, M., Seligman, A., Iancu, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30481-7 · Cited by 120
Current status and new treatment approaches in TP53 mutated AML
Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102
p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma
Jin, S., Yang, X., Li, J., Yang, W., Ma, H., & Zhang, Z. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0993-3 · Cited by 109
A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity
Yan, S., Yan, J., Liu, D., Li, X., Kang, Q., You, W., Zhang, J., Wang, L., Tian, Z., Lu, W., et al. (2021) · Theranostics · doi:10.7150/thno.59020 · Cited by 108
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
Schulz‐Heddergott, R., & Moll, U. M. (2018) · Cancers · doi:10.3390/cancers10060188 · Cited by 108
An N-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells
Uddin, M. B., Roy, K. R., Hosain, S. B., Khiste, S., Hill, R. A., Jois, S. D. S., Zhao, Y., Tackett, A. J., & Liu, Y. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.014 · Cited by 105
Strategies for targeting undruggable targets
Zhang, G., Zhang, J., Gao, Y., Li, Y., & Li, Y. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1969359 · Cited by 104
The Interplay Between Tumor Suppressor p53 and Hypoxia Signaling Pathways in Cancer
Zhang, C., Liu, J., Wang, J., Zhang, T., Xu, D., Hu, W., & Feng, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.648808 · Cited by 100
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 103
Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA
Huang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1688951 · Cited by 94
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
Monti, P., Menichini, P., Speciale, A., Cutrona, G., Fais, F., Taìana, E., Neri, A., Bomben, R., Gentile, M., Gattei, V., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593383 · Cited by 98
URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers
Ding, Z., Pan, Y., Shang, T., Jiang, T., Lin, Y., Yang, C., Pang, S., Cui, X., Wang, Y., Feng, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41852-z · Cited by 92
Mutant p53 improves cancer cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6
Sicari, D., Fantuz, M., Bellazzo, A., Valentino, E., Apollonio, M., Pontisso, I., Cristino, F. D., Ferro, M. D., Bicciato, S., Sal, G. D., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0878-3 · Cited by 91
Drugging “undruggable” genes for cancer treatment: Are we making progress?
Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 86
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
Canale, M., Andrikou, K., Priano, I., Cravero, P., Pasini, L., Urbini, M., Delmonte, A., Crinò, L., Bronte, G., & Ulivi, P. (2022) · Cancers · doi:10.3390/cancers14051143 · Cited by 97
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations
Funk, J. S., Klimovich, M., Drangenstein, D., Pielhoop, O., Hunold, P., Borowek, A., Noeparast, A., Pavlakis, E., Neumann, M. M., Balourdas, D.-I., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02039-4 · Cited by 94
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
The Emerging Landscape of p53 Isoforms in Physiology, Cancer and Degenerative Diseases
Anbarasan, T., & Bourdon, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246257 · Cited by 85
Pharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 97
Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen
Wu, D., Gallagher, D. T., Gowthaman, R., Pierce, B. G., & Mariuzza, R. A. (2020) · Nature Communications · doi:10.1038/s41467-020-16755-y · Cited by 78
The Role of p53 in Progression of Cutaneous Squamous Cell Carcinoma
Piipponen, M., Riihilä, P., Nissinen, L. M., & Kähäri, V. (2021) · Cancers · doi:10.3390/cancers13184507 · Cited by 90
Functions of p53 in pluripotent stem cells
Fu, X., Wu, S., Li, B., Xu, Y., & Liu, J. (2019) · Protein & Cell · doi:10.1007/s13238-019-00665-x · Cited by 80
Cancer Stemness: p53 at the Wheel
Ghatak, D., Ghosh, D. D., & Roychoudhury, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.604124 · Cited by 75
The Mettl3 epitranscriptomic writer amplifies p53 stress responses
Raj, N., Wang, M., Seoane, J. A., Zhao, R. L., Kaiser, A. M., Moonie, N. A., Demeter, J., Boutelle, A. M., Kerr, C. H., Mulligan, A. S., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.010 · Cited by 77
The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer
Liu, J., Zhang, C., Xu, D., Zhang, T., Chang, C., Wang, J., Liu, J., Zhang, L., Haffty, B. G., Zong, W., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164354 · Cited by 79
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
Zhang, S., Carlsen, L., Borrero, L. J. H., Seyhan, A. A., Tian, X., & El‐Deiry, W. S. (2022) · Biomolecules · doi:10.3390/biom12040548 · Cited by 75
Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2
Yang, W., Liu, W., Li, X., Yan, J., & He, W. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.05.009 · Cited by 72
Computer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 72
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
Stockhammer, P., Grant, M. J., Wurtz, A., Foggetti, G., Expósito, F., Gu, J., Zhao, H., Choi, J., Chung, S. T., Li, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.001 · Cited by 67
Patterns of mutations in TP53 mutated AML
Welch, J. S. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.09.010 · Cited by 68
Role of Dietary Antioxidants in p53‐Mediated Cancer Chemoprevention and Tumor Suppression
Merlin, J. P. J., Rupasinghe, H. P. V., Dellaire, G., & Murphy, K. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9924328 · Cited by 69
Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 72
p53’s Extended Reach: The Mutant p53 Secretome
Pavlakis, E., & Stiewe, T. (2020) · Biomolecules · doi:10.3390/biom10020307 · Cited by 66
Ceramide Signaling and p53 Pathways
Jeffries, K. A., & Krupenko, N. I. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.04.011 · Cited by 68
Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance
Xu, J., Patel, N. H., & Gewirtz, D. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238991 · Cited by 66
Structural and Drug Targeting Insights on Mutant p53
Gomes, A. S., Ramos, H., Inga, A., Sousa, E., & Saraiva, L. (2021) · Cancers · doi:10.3390/cancers13133344 · Cited by 63
A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications
Wang, M., & Attardi, L. D. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-025840 · Cited by 61
p53 partial loss-of-function mutations sensitize to chemotherapy
Klimovich, B., Merle, N., Neumann, M. M., Elmshäuser, S., Nist, A., Mernberger, M., Kazdal, D. N., Stenzinger, A., Timofeev, O. N., & Stiewe, T. (2021) · Oncogene · doi:10.1038/s41388-021-02141-5 · Cited by 61
Targeting mutant p53: a key player in breast cancer pathogenesis and beyond
Qayoom, H., Haq, B. U., Sofi, S., Jan, N., Jan, A., & Mir, M. A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01863-9 · Cited by 68
Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis
Chou, C.-W., Lin, C., Hsiao, T.-H., Lo, C.-C., Hsieh, C.-Y., Huang, C.-C., & Sher, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-56532-6 · Cited by 60
Structural diversity of p63 and p73 isoforms
Osterburg, C., & Dötsch, V. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00975-4 · Cited by 67
Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
Deben, C., Deschoolmeester, V., Waele, J. D., Jacobs, J., den Bossche, J. V., Wouters, A., Peeters, M., Rolfo, C. D., Smits, E., Lardon, F., et al. (2018) · Cancers · doi:10.3390/cancers10040126 · Cited by 59
Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties
Song, H., Wu, J., Tang, Y., Dai, Y., Xiang, X., Li, Y., Wu, L., Wu, J., Liang, Y., Xing, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9155 · Cited by 56
Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy
Li, S., Wang, A., Wu, Y., He, S., Wen, S., Zhao, M., Zhu, Y., Hu, X., Luo, Y., & Wang, G. (2023) · Immunological Reviews · doi:10.1111/imr.13274 · Cited by 61
Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease
Blandino, G., Valenti, F., Sacconi, A., & Agostino, S. D. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.011 · Cited by 60
Mutant p53 in cell-cell interactionsPreprint
Pilley, S. E., Rodríguez, T. A., & Vousden, K. H. (2021) · Genes & Development · doi:10.1101/gad.347542.120 · Cited by 54
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Timofeev, O. N., Giron, P., Lawo, S., Pichler, M., & Noeparast, A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00554-5 · Cited by 63
T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy
Sim, M. J. W., & Sun, P. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.833017 · Cited by 55
p53/MicroRNA-34 axis in cancer and beyond
Pan, W. D., Chai, B., Langping, L., Lü, Z., & Ma, Z. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15155 · Cited by 55
Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine
Hwang, L., Phang, B. H., Liew, O. W., Iqbal, J., Koh, X. H., Koh, X. Y., Othman, R., Xue, Y., Richards, M., Lane, D. P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.11.112 · Cited by 52
Self-citation
p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression
Efe, G., Dunbar, K. J., Sugiura, K., Cunningham, K. M., Carcamo, S., Karaiskos, S., Tang, Q., Cruz‐Acuña, R., Resnick‐Silverman, L., Peura, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0601 · Cited by 52
Cancer therapeutic targeting using mutant–p53-specific siRNAs
Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50
Self-citation
The role and mechanism of NAT10‐mediated ac4C modification in tumor development and progression
Gu, Z., Zou, L., Pan, X., Yu, Y., Liu, Y., Zhang, Z., Liu, J., Mao, S., Zhang, J., Guo, C., et al. (2024) · MedComm · doi:10.1002/mco2.70026 · Cited by 52
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 53
The Tumor Microenvironment: Signal Transduction
Zhang, X., Ma, H., Gao, Y., Liang, Y., Du, Y., Hao, S., & Ni, T. (2024) · Biomolecules · doi:10.3390/biom14040438 · Cited by 56
Exploring the Genetic Orchestra of Cancer: The Interplay Between Oncogenes and Tumor-Suppressor Genes
Singh, S. P., Bhaskar, R., Ghosh, S., Yarlagadda, B., Singh, D. K. K., Verma, P., Sengupta, S., Mladenov, M. I., Hadzi‐Petrushev, N., Stojchevski, R., et al. (2025) · Cancers · doi:10.3390/cancers17071082 · Cited by 63
Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets
Lu, J., Ding, Y., Chen, Y., Jiang, J., Chen, Y., Huang, Y., Wu, M., Li, C., Kong, M., Zhao, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24170-0 · Cited by 47
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia
Bomben, R., Rossi, F. M., Vit, F., Bittolo, T., D’Agaro, T., Zucchetto, A., Tissino, E., Pozzo, F., Vendramini, E., Degan, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0701 · Cited by 48
Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
Duffy, M. J., Tang, M., Rajaram, S., O’Grady, S., & Crown, J. P. (2022) · Cancers · doi:10.3390/cancers14184499 · Cited by 49
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial
Chen, A. P., Kummar, S., Moore, N., Rubinstein, L., Zhao, Y., Williams, P. M., Palmisano, A., Sims, D., Coyne, G. O., Rosenberger, C. L., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00372 · Cited by 47

Authors: Sabapathy, K., & Lane, D. P.
Affiliations: National University of Singapore (SG)
Agency for Science, Technology and Research (SG)
Corresponding author: Sabapathy, Kanaga
Lane, David P.
ORCID: Sabapathy, Kanaga
Lane, David P.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2017-09-26
Volume: 15
Issue: 1
Pages: 13-30
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2017.151
OpenAlex: W2759444489
Cited by: 517
References: 178
Citations by year: 2026: 40 · 2025: 67 · 2024: 74 · 2023: 89 · 2022: 57 · 2021: 64 · 2020: 53 · 2019: 41 · 2018: 26 · 2017: 3
FWCI: 3.53
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Research Foundation Singapore
National Medical Research Council
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: TP53 mutation, mutant p53, p53-targeted therapy, tumour suppressor, cancer therapy resistance, prognostic factors
MeSH terms: Humans, Mutation, Neoplasms, Genes, p53

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks